SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 9.99% Stake in Moleculin Biotech

Armistice Capital, LLC and Steven Boyd have disclosed a 9.99% beneficial ownership stake in Moleculin Biotech, Inc. as of December 31, 2024.

Summary

• Armistice Capital, LLC and Steven Boyd collectively reported beneficial ownership of 339,767 shares of Moleculin Biotech, Inc. common stock.
• This ownership represents 9.99% of the total outstanding common stock of Moleculin Biotech, Inc.
• The reported ownership percentage is based on the holdings as of December 31, 2024.
• Armistice Capital, LLC, as the investment manager for Armistice Capital Master Fund Ltd., exercises shared voting and dispositive power over these shares.
• Steven Boyd, as the managing member of Armistice Capital, LLC, is also deemed to beneficially own these shares.
• The securities were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing the control of Moleculin Biotech, Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the company's performance or outlook.

Positives

• No specific positives related to the issuer's performance or outlook are disclosed in this ownership filing, which primarily focuses on beneficial ownership.

Negatives

• No specific negatives related to the issuer's performance or outlook are disclosed in this ownership filing, which primarily focuses on beneficial ownership.

Risks

• No specific risks related to the issuer's operations or financial health are disclosed in this ownership filing, which is limited to beneficial ownership information.

Future Outlook

NA

Management Comments

• The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

This filing is a standard disclosure of significant beneficial ownership and does not provide broader industry context or trends.

Related Party Transactions

• Armistice Capital, LLC is the investment manager for Armistice Capital Master Fund Ltd., which directly holds the shares. Steven Boyd is the managing member of Armistice Capital, LLC. The Master Fund disclaims beneficial ownership due to its investment management agreement with Armistice Capital.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake in the company, which can influence market perception and liquidity.

Key Dates

Keywords

Moleculin Biotech, Armistice Capital, Steven Boyd, Schedule 13G, beneficial ownership, common stock, investment management